Skip directly to site content Skip directly to page options Skip directly to A-Z link Skip directly to A-Z link Skip directly to A-Z link
Volume 18, Number 4—April 2012
Research

Comparison of Escherichia coli ST131 Pulsotypes, by Epidemiologic Traits, 1967–2009

James R. JohnsonComments to Author , Marie-Hélène Nicolas-Chanoine, Chitrita DebRoy, Mariana Castanheira, Ari Robicsek, Glen Hansen, Scott Weissman, Carl Urban, Joanne Platell, Darren Trott, George Zhanel, Connie Clabots, Brian D. Johnston, Michael A. Kuskowski, and the MASTER Investigators
Author affiliations: Veterans Affairs Medical Center, Minneapolis, Minnesota, USA (J.R. Johnson, C. Clabots, B.D. Johnston, M.A. Kuskowski); University of Minnesota, Minneapolis (J.R. Johnson, B.D. Johnston, M.A. Kuskowski); Hôpital Beaujon, Clichy, France (M.-H. Nicolas-Chanoine); The Pennsylvania State University, College Park, Pennsylvania, USA (C. DebRoy); JMI Laboratories, North Liberty, Iowa, USA (M. Castanheira); NorthShore University HealthSystem, Evanston, Illinois, USA (A. Robicsek); Hennepin County Medical Center, Minneapolis (G. Hansen); University of Washington, Seattle, Washington, USA (S. Weissman); New York Hospital Queens, Flushing, New York, USA (C. Urban); New York University School of Medicine, New York, New York, USA (C. Urban); University of Queensland, Brisbane, Queensland, Australia (J. Platell); University of Adelaide, Adelaide, South Australia, Australia (D. Trott); University of Manitoba, Winnipeg, Manitoba, Canada (G. Zhanel)

Main Article

Table 7

Distribution, by antimicrobial drug resistance trait, of Escherichia coli ST131 isolates among different pulsotype groups and individual pulsotypes, 1967–2009*

Antimicrobial drug resistance trait No. (%) isolates
Total no. isolates, N = 579 High-prevalence pulsotypes, n = 327 Multiple-isolate pulsotypes, n = 474 Individual high-prevalence pulsotypes
968, n = 136 800, n = 82 812, n = 32 905, n = 19 987, n = 11 1202, n = 8 919, n = 7 955, n = 7 797, n = 6
FQ-R 462 (80) 293 (90)† 401 (85)† 133 (98)† 81 (99)† 32 (100)† 19 (100)‡ 0† 1 (13)† 7 (100)§ 1 (14)† 0 †
ESBL 272 (47) 144 (44) 219 (46) 62 (46) 12 (15)† 30 (94)† 17 (90)† 0† 3 (38) 7 (100)§ 2 (29)§ 0 ‡
blaCTX-M-15 188 (33) 102 (31) 156 (33) 38 (28) 5 (6)† 28 (88)† 16 (84)† 0‡ 0 ‡ 6 (86)§ 0 0

*Boldface indicates p <0.05 in comparison with all other isolates. Pulsotypes shown are those, among the 12 high-prevalence pulsotypes, that exhibited a significant association with >1 resistance trait. ST, sequence type; FQ-R, fluoroquinolone resistance; ESBL, extended-spectrum β-lactamase production; blaCTX-M-15, gene encoding CTX-M-15. †p<0.001 for indicated pulsotype group or pulsotype vs. all others (Fisher exact test).
‡p<0.05 for indicated pulsotype group or pulsotype vs. all others (Fisher exact test).
§p<0.01 for indicated pulsotype group or pulsotype vs. all others (Fisher exact test).

Main Article

1MASTER (Macrorestriction Analysis of ST131 for Epidemiologic Research) Investigators who contributed data are listed at the end of this article.

Page created: March 15, 2012
Page updated: March 15, 2012
Page reviewed: March 15, 2012
The conclusions, findings, and opinions expressed by authors contributing to this journal do not necessarily reflect the official position of the U.S. Department of Health and Human Services, the Public Health Service, the Centers for Disease Control and Prevention, or the authors' affiliated institutions. Use of trade names is for identification only and does not imply endorsement by any of the groups named above.
file_external